Search

Author/Creator Issa, Maher

1. Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis. Issue 7 (25th May 2019)

Authors:
Taylor, Peter C.; Weinblatt, Michael E.; Burmester, Gerd R.; Rooney, Terence P.; Witt, Sarah; Walls, Chad D.; Issa, Maher; Salinas, Claudia A.; Saifan, Chadi; Zhang, Xin; Cardoso, Anabela; González‐Gay, Miguel A.; Takeuchi, Tsutomu
Journal:
Arthritis & rheumatology
Issue:
Volume 71:Issue 7(2019)
Page Start:
1042
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib. Issue 3 (6th October 2020)

Authors:
Kay, Jonathan; Harigai, Masayoshi; Rancourt, Josh; Dickson, Christina; Melby, Thomas; Issa, Maher; de la Torre, Inmaculada; Isaka, Yoshitaka; Cardoso, Anabela; Saifan, Chadi; Keystone, Edward C; van Vollenhoven, Ronald F; Giles, Jon T; Huizinga, Tom WJ; Kremer, Joel M
Journal:
RMD open
Issue:
Volume 6:Issue 3(2020)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Characterization and Changes of Lymphocyte Subsets in Baricitinib‐Treated Patients With Rheumatoid Arthritis: An Integrated Analysis. Issue 12 (22nd October 2018)

Authors:
Tanaka, Yoshiya; McInnes, Iain B.; Taylor, Peter C.; Byers, Nicole L.; Chen, Lei; de Bono, Stephanie; Issa, Maher; Macias, William L.; Rogai, Veronica; Rooney, Terence P.; Schlichting, Douglas E.; Zuckerman, Steven H.; Emery, Paul
Journal:
Arthritis & rheumatology
Issue:
Volume 70:Issue 12(2018)
Page Start:
1923
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis. Issue 7 (30th April 2019)

Authors:
Tanaka, Yoshiya; Fautrel, Bruno; Keystone, Edward C; Ortmann, Robert A; Xie, Li; Zhu, Baojin; Issa, Maher; Patel, Himanshu; Gaich, Carol L; de Bono, Stephanie; Rooney, Terence P; Taylor, Peter C
Journal:
Annals of the rheumatic diseases
Issue:
Volume 78:Issue 7(2019)
Page Start:
890
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis. Issue 7 (30th July 2019)

Authors:
Tanaka, Yoshiya; Fautrel, Bruno; Keystone, Edward C; Ortmann, Robert A; Xie, Li; Zhu, Baojin; Issa, Maher; Patel, Himanshu; Gaich, Carol L; de Bono, Stephanie; Rooney, Terence P; Taylor, Peter C
Journal:
Annals of the rheumatic diseases
Issue:
Volume 78:Issue 7(2019)
Page Start:
890
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Efficacy and Safety of Long‐Term Baricitinib With and Without Methotrexate for the Treatment of Rheumatoid Arthritis: Experience With Baricitinib Monotherapy Continuation or After Switching From Methotrexate Monotherapy or Baricitinib Plus Methotrexate. Issue 8 (29th July 2020)

Authors:
Fleischmann, Roy; Takeuchi, Tsutomu; Schiff, Michael; Schlichting, Douglas; Xie, Li; Issa, Maher; Stoykov, Ivaylo; Lisse, Jeffrey; Martinez‐Osuna, Pindaro; Rooney, Terence; Zerbini, Cristiano A. F.
Journal:
Arthritis care & research
Issue:
Volume 72:Issue 8(2020)
Page Start:
1112
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Infections in baricitinib clinical trials for patients with active rheumatoid arthritis. Issue 10 (11th August 2020)

Authors:
Winthrop, Kevin L; Harigai, Masayoshi; Genovese, Mark C; Lindsey, Stephen; Takeuchi, Tsutomu; Fleischmann, Roy; Bradley, John D; Byers, Nicole L; Hyslop, David L; Issa, Maher; Nishikawa, Atsushi; Rooney, Terence P; Witt, Sarah; Dickson, Christina L; Smolen, Josef S; Dougados, Maxime
Journal:
Annals of the rheumatic diseases
Issue:
Volume 79:Issue 10(2020)
Page Start:
1290
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials. (31st December 2023)

Authors:
Bieber, Thomas; Katoh, Norito; Simpson, Eric L.; de Bruin-Weller, Marjolein; Thaçi, Diamant; Torrelo, Antonio; Sontag, Angelina; Grond, Susanne; Issa, Maher; Lu, Xiaoyu; Cardillo, Tracy; Holzwarth, Katrin; Thyssen, Jacob P.
Journal:
Journal of dermatological treatment
Issue:
Volume 34:Number 1(2023)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. Issue 3 (27th October 2021)

Authors:
Taylor, Peter C; Takeuchi, Tsutomu; Burmester, Gerd R; Durez, Patrick; Smolen, Josef S; Deberdt, Walter; Issa, Maher; Terres, Jorge Ross; Bello, Natalia; Winthrop, Kevin L
Journal:
Annals of the rheumatic diseases
Issue:
Volume 81:Issue 3(2022)
Page Start:
335
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis. (June 2020)

Authors:
Genovese, Mark C; Smolen, Josef S; Takeuchi, Tsutomu; Burmester, Gerd; Brinker, Dennis; Rooney, Terence P; Zhong, Jinglin; Daojun, Mo; Saifan, Chadi; Cardoso, Anabela; Issa, Maher; Wu, Wen-Shuo; Winthrop, Kevin L
Journal:
Lancet
Issue:
Volume 2:Number 6(2020)
Page Start:
e347
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗